174 related articles for article (PubMed ID: 23818648)
1. Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.
Tomberli B; Cecchi F; Sciagrà R; Berti V; Lisi F; Torricelli F; Morrone A; Castelli G; Yacoub MH; Olivotto I
Eur J Heart Fail; 2013 Dec; 15(12):1363-73. PubMed ID: 23818648
[TBL] [Abstract][Full Text] [Related]
2. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
3. Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study.
Graziani F; Laurito M; Pieroni M; Pennestrì F; Lanza GA; Coluccia V; Camporeale A; Pedicino D; Verrecchia E; Manna R; Crea F
J Am Soc Echocardiogr; 2017 Mar; 30(3):282-291. PubMed ID: 28069318
[TBL] [Abstract][Full Text] [Related]
4. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
5. Clinical study of left ventricular structure and function in patients with Anderson-Fabry disease before and after enzyme replacement therapy.
Huang S; Wang J; Zhang W; Gao F; Chen Y; Shui W; Xing X; Chen S; Mu Y
J Clin Ultrasound; 2024 Jan; 52(1):20-29. PubMed ID: 37883130
[TBL] [Abstract][Full Text] [Related]
6. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.
Timmer SA; Germans T; Brouwer WP; Lubberink M; van der Velden J; Wilde AA; Christiaans I; Lammertsma AA; Knaapen P; van Rossum AC
Eur J Heart Fail; 2011 Dec; 13(12):1283-9. PubMed ID: 22021246
[TBL] [Abstract][Full Text] [Related]
7. Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
Kampmann C; Baehner F; Whybra C; Martin C; Wiethoff CM; Ries M; Gal A; Beck M
J Am Coll Cardiol; 2002 Nov; 40(9):1668-74. PubMed ID: 12427421
[TBL] [Abstract][Full Text] [Related]
8. Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy.
Gruner C; Verocai F; Carasso S; Vannan MA; Jamorski M; Clarke JT; Care M; Iwanochko RM; Rakowski H
Echocardiography; 2012 Aug; 29(7):810-7. PubMed ID: 22497597
[TBL] [Abstract][Full Text] [Related]
9. Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease: a quantitative analysis of clinical 82Rb PET/CT studies.
Fukushima K; Javadi MS; Higuchi T; Bravo PE; Chien D; Lautamäki R; Merrill J; Nekolla SG; Bengel FM
J Nucl Med; 2012 Jun; 53(6):887-93. PubMed ID: 22562499
[TBL] [Abstract][Full Text] [Related]
10. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.
Sado DM; White SK; Piechnik SK; Banypersad SM; Treibel T; Captur G; Fontana M; Maestrini V; Flett AS; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Neubauer S; Elliott PM; Moon JC
Circ Cardiovasc Imaging; 2013 May; 6(3):392-8. PubMed ID: 23564562
[TBL] [Abstract][Full Text] [Related]
11. Onset and progression of the Anderson-Fabry disease related cardiomyopathy.
Kampmann C; Linhart A; Baehner F; Palecek T; Wiethoff CM; Miebach E; Whybra C; Gal A; Bultas J; Beck M
Int J Cardiol; 2008 Nov; 130(3):367-73. PubMed ID: 18572264
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy.
Kjaer A; Meyer C; Wachtell K; Olsen MH; Ibsen H; Opie L; Holm S; Hesse B
Am J Cardiol; 2005 Dec; 96(12):1692-8. PubMed ID: 16360359
[TBL] [Abstract][Full Text] [Related]
13. Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.
Putko BN; Yogasundaram H; Chow K; Pagano J; Khan A; Paterson DI; Thompson RB; Oudit GY
Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1129-36. PubMed ID: 25750198
[TBL] [Abstract][Full Text] [Related]
14. Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects.
Palmieri V; Storto G; Arezzi E; Pellegrino T; Mancini M; Di Minno G; Ferrara AL; Cuocolo A; Celentano A
J Hum Hypertens; 2005 Dec; 19(12):941-50. PubMed ID: 16079883
[TBL] [Abstract][Full Text] [Related]
15. Basal Segmental Longitudinal Strain: A Marker of Subclinical Myocardial Involvement in Anderson-Fabry Disease.
Zada M; Lo Q; Boyd AC; Bradley S; Devine K; Denaro CP; Sadick N; Richards DAB; Tchan MC; Thomas L
J Am Soc Echocardiogr; 2021 Apr; 34(4):405-413.e2. PubMed ID: 33242609
[TBL] [Abstract][Full Text] [Related]
16. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis.
Dorbala S; Vangala D; Bruyere J; Quarta C; Kruger J; Padera R; Foster C; Hanley M; Di Carli MF; Falk R
JACC Heart Fail; 2014 Aug; 2(4):358-67. PubMed ID: 25023822
[TBL] [Abstract][Full Text] [Related]
17. Epicardial coronary artery size in hypertensive and physiologic left ventricular hypertrophy.
Kozakova M; Paterni M; Bartolomucci F; Morizzo C; Rossi G; Galetta F; Palombo C
Am J Hypertens; 2007 Mar; 20(3):279-84. PubMed ID: 17324740
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease.
Recio-Mayoral A; Rimoldi OE; Camici PG; Kaski JC
JACC Cardiovasc Imaging; 2013 Jun; 6(6):660-7. PubMed ID: 23643286
[TBL] [Abstract][Full Text] [Related]
19. Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients.
Esposito R; Galderisi M; Santoro C; Imbriaco M; Riccio E; Maria Pellegrino A; Sorrentino R; Lembo M; Citro R; Angela Losi M; Spinelli L; Trimarco B; Pisani A
Eur Heart J Cardiovasc Imaging; 2019 Apr; 20(4):438-445. PubMed ID: 30085001
[TBL] [Abstract][Full Text] [Related]
20. [Cardiac hypertrophy and coronary reserve in endurance athletes].
Toraa M; Pouillard F; Merlet P; Friemel F
Can J Appl Physiol; 1999 Feb; 24(1):87-95. PubMed ID: 10084848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
